IFx 2.0：銷售預測與市場規模（2034 年）

推動IFx 2.0成長的關鍵因素

1. 針對查核點抑制劑抗藥性的新型作用機制

• IFx-2.0 是一種先天免疫促效劑/局部癌症疫苗，旨在克服對查核點抑制劑 (CPI)（如Pembrolizumab）的原發性抗藥性。
• 腫瘤內給藥後，可誘導全身性抗腫瘤免疫反應（遠端效應）。

成長洞察：

• 解決一項重大的未滿足醫療需求：約 40-50% 的患者對第一線查核點抑制劑沒有反應。
• 它確立了強大的市場地位，不是作為一種競爭藥物，而是作為一種能夠實現聯合治療的治療方法。

2. 早期臨床試驗中徵兆出顯著療效

• 進行性/轉移性默克爾細胞癌（MCC）的Ib期試驗：
• CPI抗藥性患者的整體緩解率（ORR）：63%（2例完全緩解，5例部分緩解）
• 療效永續長達 23-33 個月
• 補充數據：
• 在接受抗 PD(L)-1 治療的特定亞組中，觀察到的反應率高達 80%。

3. 過渡到 III 期試驗（處於核准申請階段的資產）

• 2025年，我們根據FDA的特殊通訊協定評估（SPA）啟動了III期加速核准試驗。
• 主要終點：整體緩解率（ORR）適合快速核准。

成長洞察：

• 向發展後期階段的過渡導致以下方面顯著增加：
• 商業化潛力
• 短期價值轉折點

4. 與標準治療方案合併治療（基於 KEYTRUDA 的治療方案）

• 在本 III 期試驗中，我們將比較和評估 IFx-2.0Pembrolizumab單抗與Pembrolizumab單藥治療作為 MCC 一線治療的療效。

成長洞察：

• 以價值超過300億美元的重磅藥物為基礎。
• 如果核准，實施速度將會加快。
• 易於融入現有治療模式

5. 孤兒藥認定及監理優惠待遇

• 我們已獲得美國食品藥物管理局 (FDA) 授予的治療黑色素瘤的孤兒藥資格（2026 年）。

主要優勢：

• 市場獨佔權（在美國為7年）
• 費用減免和開發獎勵

6. 具有作為跨多種腫瘤類型的平台的潛力

• 目標疾病：
• 默克細胞癌（主要適應症）
• 皮膚鱗狀細胞癌
• 惡性黑色素瘤
• 該試驗包括對 CPI 抗藥性的患者組和未接受過治療的患者組。

IFx 2.0 的最新進展

• 2026 年 2 月，TuHURA Biosciences 宣布，FDA 孤兒藥開發辦公室已授予 IFx-2.0 孤兒藥資格認定 (ODD)，用於治療 IIB 至 IV 期皮膚黑色素瘤。
• 2025 年 6 月，TuHURA Biosciences 宣布，莫菲特癌症中心已在 2025 年美國臨床腫瘤學會 (ASCO) 年會上展示了其計劃開展的 III 期加速核准試驗的海報。

本報告全面深入分析了IFx 2.0及其在七國集團（美國、歐盟四國（德國、法國、義大利、西班牙）、英國和日本）的潛在適應症，包括默克細胞癌、基底細胞癌、惡性黑色素瘤和鱗狀細胞癌。報告詳細分析了IFx 2.0在七國集團市場的現有應用情況、潛在適應症的市場准入情況以及2020年至2034年的市場表現，並詳細描述了IFx 2.0的潛在適應症。此外，報告還分析了IFx 2.0的銷售預測、作用機制、劑量和給藥方法、研發及其他活動（包括監管里程碑）、未來市場評估、SWOT分析、分析師觀點、競爭對手概覽、各適應症中其他新興治療方法的概述以及市場促進因素。

目錄

第1章：報告概述

第 2 章 IFx 2.0 概述：Merkel氏細胞癌、基底細胞癌、惡性黑色素瘤、鱗狀細胞癌等的潛在適應症。

• 產品詳情
• 臨床開發
  • 臨床試驗
  • 臨床試驗資訊
  • 安全性和有效性
• 其他發展活動
• 產品概述

第3章 IFx 2.0：競爭格局（已上市療法）

第4章 IFx 2.0：競爭格局（後期研發藥物）

第5章 IFx 2.0：市場估值

• 潛在適應症的市場展望
• 對七國集團國家的分析
  • 七大主要國家潛在適應症的市場規模
• 各國市場分析
  • 潛在適應症的市場規模：美國
  • 潛在適應症的市場規模：德國
  • 潛在適應症的市場規模：英國

第6章 IFx 2.0：SWOT 分析

第7章 分析師觀點

第8章附錄

第9章：DelveInsight 服務

第10章 免責聲明

第11章：關於 DelveInsight

第12章：報告購買選項

Key Factors Driving IFx 2.0 Growth

1. Novel mechanism targeting checkpoint inhibitor resistance

• IFx-2.0 is an innate immune agonist / in situ cancer vaccine designed to overcome primary resistance to checkpoint inhibitors (CPIs) such as pembrolizumab.
• It induces systemic anti-tumor immune responses (abscopal effect) after intratumoral injection.

Growth implication:

• Addresses a major unmet need: ~40-50% of patients do not respond to first-line checkpoint inhibitors.
• Strong positioning as a combination-enabling therapy, not a competitor.

2. Strong early clinical efficacy signals

• Phase Ib trial in advanced/metastatic Merkel cell carcinoma (MCC):
• Overall response rate (ORR): 63% (2 CR, 5 PR) in CPI-refractory patients
• Durable responses lasting up to 23-33 months
• Additional data:
• Up to 80% response rates in certain subgroups when rechallenged with anti-PD(L)-1 therapy

3. Advancement into Phase III (registration-stage asset)

• Phase III accelerated approval trial initiated in 2025 under FDA Special Protocol Assessment (SPA).
• Primary endpoint: Overall Response Rate (ORR) suitable for accelerated approval.

Growth implication:

• Late-stage development significantly increases:
• Probability of commercialization
• Near-term value inflection

4. Combination with standard-of-care (KEYTRUDA backbone)

• Phase III evaluates IFx-2.0 + pembrolizumab vs pembrolizumab alone in first-line MCC.

Growth implication:

• Leveraging a $30B+ blockbuster therapy backbone ->
• Faster adoption if approved
• Easier integration into existing treatment paradigms

5. Orphan Drug Designation and regulatory advantages

• Granted FDA Orphan Drug Designation (2026) for melanoma.

Benefits include:

• Market exclusivity (7 years in the US)
• Fee reductions and development incentives

6. Platform potential across multiple tumor types

• Studied in:
• Merkel cell carcinoma (lead indication)
• Cutaneous squamous cell carcinoma
• Melanoma
• Trials include both checkpoint inhibitor-resistant and naive populations

IFx 2.0 Recent Developments

• In February 2026, TuHURA Biosciences announced that the US Food and Drug Administration's (FDA) Office of Orphan Products Development had granted Orphan Drug Designation (ODD) to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma.
• In June 2025, TuHURA Biosciences announced that Moffitt Cancer Center presented a Trial in Progress poster of the Company's planned Phase III accelerated approval trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

"IFx 2.0 Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of IFx 2.0 for potential indication like Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer in the 7MM. A detailed picture of IFx 2.0's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the IFx 2.0 for potential indications. The IFx 2.0 market report provides insights about IFx 2.0's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IFx 2.0 performance, future market assessments inclusive of the IFx 2.0 market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IFx 2.0 sales forecasts, along with factors driving its market.

IFx 2.0 Drug Summary

IFx 2.0 is an investigational, first-in-class DNA plasmid-based immunotherapy developed by Inhibikase Therapeutics (via its subsidiary IFx Biotechnologies) for the treatment of autoimmune and inflammatory diseases. The therapy is designed to activate Toll-like receptor 9 (TLR9), a key component of the innate immune system, by introducing a non-coding plasmid DNA that stimulates a controlled immune response. Unlike traditional immunosuppressive therapies, IFx-2.0 aims to reprogram immune signaling pathways to restore immune tolerance and reduce chronic inflammation. It is being investigated primarily for dermatologic conditions such as Vitiligo, where localized administration (typically via intradermal injection) may promote repigmentation by modulating immune-mediated melanocyte destruction. Early-stage studies have shown encouraging signs of immune activation and clinical response, supporting its potential as a novel disease-modifying therapy in autoimmune indications. The report provides IFx 2.0's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the IFx 2.0 Market Report

The report provides insights into:

• A comprehensive product overview including the IFx 2.0 MoA, description, dosage and administration, research and development activities in potential indication like Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer.
• Elaborated details on IFx 2.0 regulatory milestones and other development activities have been provided in IFx 2.0 market report.
• The report also highlights IFx 2.0's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The IFx 2.0 market report also covers the patents information, generic entry and impact on cost cut.
• The IFx 2.0 market report contains current and forecasted IFx 2.0 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The IFx 2.0 market report also features the SWOT analysis with analyst views for IFx 2.0 in potential indications.

Methodology:

The IFx 2.0 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IFx 2.0 Analytical Perspective by DelveInsight

• In-depth IFx 2.0 Market Assessment

This IFx 2.0 sales market forecast report provides a detailed market assessment of IFx 2.0 for potential indication like Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IFx 2.0 sales data uptil 2034.

• IFx 2.0 Clinical Assessment

The IFx 2.0 market report provides the clinical trials information of IFx 2.0 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

IFx 2.0 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

IFx 2.0 Market Potential & Revenue Forecast

• Projected market size for the IFx 2.0 and its key indications
• Estimated IFx 2.0 sales potential (IFx 2.0 peak sales forecasts)
• IFx 2.0 Pricing strategies and reimbursement landscape

IFx 2.0 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• IFx 2.0 Market positioning compared to existing treatments
• IFx 2.0 Strengths & weaknesses relative to competitors

IFx 2.0 Regulatory & Commercial Milestones

• IFx 2.0 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

IFx 2.0 Clinical Differentiation

• IFx 2.0 Efficacy & safety advantages over existing drugs
• IFx 2.0 Unique selling points

IFx 2.0 Market Report Highlights

• In the coming years, the IFx 2.0 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The IFx 2.0 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IFx 2.0's dominance.
• Other emerging products for Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer are expected to give tough market competition to IFx 2.0 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IFx 2.0 in potential indications.
• Analyse IFx 2.0 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted IFx 2.0 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IFx 2.0 in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of IFx 2.0? How strong is IFx 2.0's clinical and commercial performance?
• What is IFx 2.0's clinical trial status in each individual indications such as Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IFx 2.0 Manufacturers?
• What are the key designations that have been granted to IFx 2.0 for potential indications? How are they going to impact IFx 2.0's penetration in various geographies?
• What is the current and forecasted IFx 2.0 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of IFx 2.0 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to IFx 2.0 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is IFx 2.0? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. IFx 2.0 Overview in potential indication like Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer

• 2.1. Product Detail
• 2.2. IFx 2.0 Clinical Development
  • 2.2.1. IFx 2.0 Clinical studies
  • 2.2.2. IFx 2.0 Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. IFx 2.0 Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging IFx 2.0 Therapies)

5. IFx 2.0 Market Assessment

• 5.1. IFx 2.0 Market Outlook in potential indications
• 5.2. 7MM Analysis
  • 5.2.1. IFx 2.0 Market Size in the 7MM for potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. IFx 2.0 Market Size in the United States for potential indications
  • 5.3.2. IFx 2.0 Market Size in Germany for potential indications
  • 5.3.3. IFx 2.0 Market Size in France for potential indications
  • 5.3.4. IFx 2.0 Market Size in Italy for potential indications
  • 5.3.5. IFx 2.0 Market Size in Spain for potential indications
  • 5.3.6. IFx 2.0 Market Size in the United Kingdom for potential indications
  • 5.3.7. IFx 2.0 Market Size in Japan for potential indications

6. IFx 2.0 SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables

• Table 1: IFx 2.0, Clinical Trial Description, 2023
• Table 2: IFx 2.0, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: IFx 2.0's pricing and cost Assumptions
• Table 6: IFx 2.0's Sales Analysis in the 7MM, in USD million (2020-2034)
• Table 7: IFx 2.0 Market Size in the US, in USD million (2020-2034)
• Table 8: IFx 2.0 Market Size in Germany, in USD million (2020-2034)
• Table 9: IFx 2.0 Market Size in France, in USD million (2020-2034)
• Table 10: IFx 2.0 Market Size in Italy, in USD million (2020-2034)
• Table 11: IFx 2.0 Market Size in Spain, in USD million (2020-2034)
• Table 12: IFx 2.0 Market Size in the UK, in USD million (2020-2034)
• Table 13: IFx 2.0 Market Size in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: IFx 2.0's Sales Analysis in the 7MM, USD million (2020-2034)
• Figure 2: IFx 2.0 Market Size in the United States, USD million (2020-2034)
• Figure 3: IFx 2.0 Market Size in Germany, USD million (2020-2034)
• Figure 4: IFx 2.0 Market Size in France, USD million (2020-2034)
• Figure 5: IFx 2.0 Market Size in Italy, USD million (2020-2034)
• Figure 6: IFx 2.0 Market Size in Spain, USD million (2020-2034)
• Figure 7: IFx 2.0 Market Size in the United Kingdom, USD million (2020-2034)
• Figure 8: IFx 2.0 Market Size in Japan, USD million (2020-2034)